Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q4 FY2026 Earnings Presentation
25 slides from Lincoln Pharmaceuticals's earnings presentation, 2026
Slide 1: Q4 FY2026 Earnings Presentation
Q4 FY2026 PHARMACEUTICALS LTD Earnings Presentation HEALTHCARE FORALL GROWING IS COMMITEMENT. www.lincolnpharma.com
Slide 2: Disclaimer
Disclaimer The information, statements and analysis made in this presentation describing Company’s objectives, projections and estimates are forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which cou
Slide 3: Corporate Overview
Corporate Overview Background Product Portfolio Manufacturing Exports Established in the year 1979, 1700 registered products Manufacturing facility at Khatraj, Exports contribute 58.5% in FY26; Lincoln Pharma has developed and another 700 in pipeline. Ahmedabad and Mehsana, Gujarat. Domestic Sales c
Slide 4: Q4 and FY26 Business Performance & Future Road Map
Q4 and FY26 Business Performance & Future Road Map • During Q4 FY26, Net profit of the company was reported at Rs. 11.63 crore (0.52% growth Y-o-Y), EBITDA at Rs. 20.66 crore (4.14% growth Y-o-Y), and Total Income of Rs. 183.08 crore (13.50% growth Y-o-Y). • During FY26, Net profit of the company wa
Slide 5: Q4 FY26 Results
Q4 FY26 Results Total Income EBITDA NET PROFIT 161.30 183.08 19.84 20.66 11.57 11.63 Q4FY25 Q4FY26 Q4FY25 Q4FY26 Q4FY25 Q4FY26 Fig (RsCr) Q4 FY2026 Earning Presentation
Slide 6: FY26 Results
FY26 Results Total Income EBITDA NET PROFIT 645.71 704.48 123.97 131.14 82.35 87.89 FY25 FY26 FY25 FY26 FY25 FY26 Fig (RsCr) Q4 FY2026 Earning Presentation
Slide 7: Q4 FY26 Performance – Focused Therapeutic Areas
Q4 FY 26 Performance – Focused Therapeutic Areas Therapy Area Q4 FY26 Q4 FY25 General Anti Infectives 32.7% 26.3% Respiratory Systems 8.1% 8.3% 26.50% 26.30% 28.60% Alimentary Tract andMetabolism 6.5% 6.3% 32.70% Genito Urinary System and Sex Hormones 1.2% 1.3% Musculo-Skeletal System 12.2% 16.7% Q4
Slide 8: Q4 & FY26 Performance Overview
Q4 & FY26 Performance Overview FINANCIAL PERFORMANCE (Rs in Cr.) PARTICULARS Q4 Y-o-Y 12 Months Y-o-Y FY2026 FY2025 Growth (%) FY2026 FY2025 Growth (%) Total Income 183.05 161.30 13.50% 704.48 645.71 9.10% EBITDA 20.66 19.84 4.14% 131.14 123.97 5.78% Profit BeforeTax 16.70 16.25 2.77% 115.63 109.19
Slide 9: About Lincoln Pharmaceuticals Ltd
AboutLincoln Pharmaceuticals Ltd Providing Affordable And Innovative Medicines For Healthier Lives. Vision To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging strategic alliances both domestically and internationally. Mission Focused on delivering o
Slide 10: Key Milestones
Key Milestones 1979 1996-97 2010-11 2016-17 Listed on NSE. Domestic marketexpansion; Install 2.1 MW windmill Launched nextgeneration Received WHO-GMPfor Covered 80% of India market. in addition to 6000 progesterone therapy - plant/production unit. KVA in 2009. ProlinSpray. Lincoln wasincorporated an
Slide 11: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap CAPEX The company has completed the expansion of its Cephalosporin plant in Mehsana, Gujarat, and has commenced commercial production, with sales initiated in domestic markets. Plans are underway to register the product for export to multiple countries. C
Slide 12: Five Years Financial Overview
Lincoln Pharmaceuticals Ltd – Five Years Financial Overview Year Total Income EBITDA Net Profit EPS Share Price FY 26 704.48 131.14 87.89 43.88 564.35 FY 21 429.84 88.12 60.41 30.20 224.70 5 Yrs CAGR 10.37% 8.28% 7.79% 7.76% 20.22% Book Yalue (Per Share) Market Cap (Rs Cr) Net Debt (Rs Cr) 378 335 1
Slide 13: Business Revenue Mix
Business Revenue Mix FY13 FY19 FY26 45.0% 41.5% 25.5% 58.5% 74.5% 55.0% DOMESTIC SALES EXPORT Q4 FY2026 Earning Presentation
Slide 14: Global Footprints
Global Footprints Presence over 60+ countries in Europe, Canada, Latin & North America, Africa, Asia Pacific, South East Asia, and 26 states across India. Srinagar Jammu Chandigarh Uttrakhand North America: Ambala Ghaziabad Europe: Delhi Canada. France. Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad
Slide 15: Research & Development
Research & Development NDDS Formulations Introduced First Time In India by Lincoln Anti-Fungal VaginaSpray. Diclofenac RectalSpray. Sildenafil Oral Spray. Ondansetron Hydrochloride Oral Spray (DOMI-UP). Paracetamol 1000mg Programmed ReleaseTablet (PA-12). Micronized Progesterone Vaginal Spray (PROLI
Slide 16: Innovations – Lincoln Pharma
Innovations – LINCOLN PHARMA Q4 FY2026 Earning Presentation
Slide 17: New Launches – Domestic Market
New Launches – Domestic Market Q4 FY2026 Earning Presentation
Slide 18: New Launches – International Markets
New Launches – International Markets Q4 FY2026 Earning Presentation
Slide 19: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough &Cold/ Dermatologist Gyneacological Sterile Ophthalmic Gastro Intestinal Anti Allergic/ Preparation Products Eye Drops/ Range Anti-asthmatics Ointment Vitamins/ Anti-bacterial/ Anti-viral/ Analgesic/ Anti-Malarial M inerals/ Otology Anti-fungal Anti-pyreti
Slide 20: Best In Class Facilities – Khatraj, Gujarat
Best In Class Facilities – Khatraj, Gujarat Certification EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015; ISO-14001:2015 and ISO-45001:2018 Certified. R&D Center Approved by Government of India;Team of 30 plus scientists for R&D. Green Energy Dosage Forms Produced at Unit 1 Dosage Forms Produced at U
Slide 21: Best in Class Facilities – Mehsana, Gujarat
Best in Class Facilities – Mehsana, Gujarat WHO-GMP Certified; BOMRA Certified; ISO 9001:2015; ISO-14001:2015 and Certification ISO-45001:2018 Certified. Approved Team of 10 plus scientists for R&D. R&D Center Dosage Forms Produced at Unit 3 OSD and Dry Powder Injection Description Size Annual Capac
Slide 22: Financial Highlights
Financial Highlights TOTAL INCOME NET PROFIT 93.4 87.9 704.5 82.4 615.0 645.7 72.9 532.8 69.4 482.1 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 EBITDA NET WORTH Fig (RsCr) 758.0 134.3 131.1 671.7 124.0 592.8 105.5 111.7 502.5 432.9 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Q4 FY2026 Ea
Slide 23: Profitability Ratios
Profitability Ratios EBITDA MARGIN PAT MARGIN 21.9% 21.0% 21.8% 14.4% 15.2% 19.2% 18.6% 13.7% 12.8% 12.5% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 ROCE RONW 21.9% 19.9% 20.4% 16.0% 15.7% 14.5% 16.1% 15.0% 12.3% 11.8% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Q4 FY2026 Earning Presen
Slide 24: Share Holding Information
Share Holding Information Particulars March 2026 March 2025 Investor Category No of Shareholders No of Shares Held Holding (%) No of Shareholders No of Shares Held Holding (%) Promoter Group 25 99,69,930 49.78% 25 99,69,930 49.78% Public Holding 28,278 1,00,59,798 50.22% 31,842 1,00,59,798 50.22% To
Slide 25: Location
Location Corporate Office Lincoln House B/h Satyam Complex, Science City Road, Sola Ahmedabad - 380060,Gujarat, India. Phone: +91 - 79 - 4107 8000 l Fax: +91- 79 - 4107 8062 Email: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit Shah Gopal Modi CFO, Lincoln Pharm
Lincoln Pharmaceuticals — Q4 FY2026 Earnings Presentation on 6ix